COVID-19 Update References

1. Leung, N.H.L., Chu, D.K.W., Shiu, E.Y.C. et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med 26, 676–680 (2020).


3. Feldstein LR et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020; 383:334-46. DOI: 10.1056/NEJMoa2021680



6. Spagnolo, P. Pulmonary fibrosis secondary to COVID-19: a call to arms? May 15, 2020

7. Yanqun W et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. Published July 7, 2020 J Clin Invest. 2020.

8. Chu DK. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet 2020; 395: 1973–87

9. Liu K. Viral dynamics in mild and severe cases of COVID-19. 2020. The Lancet. DOI:

10. Heald-Sargent T, Muller WJ, Zheng X, Rippe J, Patel AB, Kociolek LK. Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19). JAMA Pediatr. Published online July 30, 2020. doi:10.1001/jamapediatrics.2020.3651

11. Guerra FM, Bolotin S, Lim G, et al. The basic reproduction number (R0) of measles: a systematic review. The Lancet. Infectious Diseases. 2017 Dec;17(12):e420-e428. DOI: 10.1016/s1473-3099(17)30307-9.

12. WHO. Draft landscape of COVID-19 candidate vaccines. 6 July 2020

13. Geleris J et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 2020;382:2411-8. DOI: 10.1056/NEJMoa2012410

14. Cavalcanti AB et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. DOI: 10.1056/NEJMoa2019014

15. Boulware DR et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. DOI: 10.1056/NEJMoa2016638

16. Beigel JH et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. DOI: 10.1056/NEJMoa2007764

17. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. Published online June 03, 2020. doi:10.1001/jama.2020.10044

18. Sette, A., Crotty, S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat Rev Immunol 20, 457–458 (2020).

19. Grifoni, A et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. 2020. Cell 181, 1489–1501